Protocol Ledger

NCT06533826 · Phase II · RECRUITING

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

Interventional Phase II clinical trial protocol NCT06533826 sponsored by Ana C Garrido-Castro, MD in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-10-29 Enrollment: 357 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06533826
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)357 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06533826
Protocol FieldVerified Registry Value
NCT IdentifierNCT06533826
Consolidated Lead SponsorAna C Garrido-Castro, MD
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment357 participants (ESTIMATED)
Registered Start Date2024-10-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI